The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Open accessAbstract
Purpose: Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcinoma. This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. Methods: Eligible patients had primary stage III or IV or recurrent HER2/neu-positive disease. Participants were randomly assigned to receive carboplatin-paclitaxel (control arm) for six cycles with or without intravenous trastuzumab (experimental arm) until progression or unacceptable toxicity. The primary end point was progression-free survival, which was assessed for differences between treatment arms via one-sided log-rank tests. Results: From August 2011 to March 2017, 61 patients were randomly assigned. Forty progression-free survival–related events occurred among 58 evaluable participants. Among all patients, median progression-free survival was 8.0 months (control) versus 12.6 months (experimental; P = .005; hazard ratio [HR], 0.44; 90% CI, 0.26 to 0.76). Similarly, median progression-free survival was 9.3 (control) versus 17.9 (experimental) months among 41 patients with stage III or IV disease undergoing primary treatment ( P = .013; HR, 0.40; 90% CI, 0.20 to 0.80) and 6.0 (control) versus 9.2 months (experimental), respectively, among 17 patients with recurrent disease ( P = .003; HR, 0.14; 90% CI, 0.04 to 0.53). Toxicity was not different between treatment arms, and no unexpected safety signals emerged. Conclusion: Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival. These encouraging results deserve further investigation to determine their impact on overall survival in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationRevised FIGO staging for carcinoma of the vulva, cervix, and endometrium
Pecorelli, S. (2009) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2009.02.012 · Cited by 2,881
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
Hamilton, C. A., Cheung, M. K., Osann, K., Chen, L., Teng, N. N., Longacre, T. A., Powell, M. A., Hendrickson, M. R., Kapp, D. S., & Chan, J. K. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603012 · Cited by 644
Treatment allocation by minimisation
Altman, D. G., & Bland, J. M. (2005) · BMJ · doi:10.1136/bmj.330.7495.843 · Cited by 550
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
Zhao, S., Choi, M., Overton, J. D., Bellone, S., Roque, D. M., Cocco, E., Guzzo, F., English, D. P., Varughese, J., Gasparrini, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222577110 · Cited by 320
Self-citationSantin, A. D., Zhan, F., Bellone, S., Palmieri, M., Cane, S., Bignotti, E., Anfossi, S., Gokden, M., Dunn, D., Roman, J. J., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20408 · Cited by 313
Self-citationFleming, G. F., Sill, M. W., Darcy, K. M., McMeekin, D. S., Thigpen, J. T., Adler, L. M., Berek, J. S., Chapman, J. A., DiSilvestro, P. A., Horowitz, I. R., et al. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.025 · Cited by 300
Hoskins, P. J., Swenerton, K. D., Pike, J. A., Wong, F., Lim, P., Acquino-Parsons, C., & Lee, N. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4048 · Cited by 275
Carcangiu, M. L., & Chambers, J. T. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90130-b · Cited by 211
Santin, A. D., Bellone, S., Roman, J. J., McKenney, J. K., & Pecorelli, S. (2008) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2008.04.008 · Cited by 198
Self-citationGrushko, T. A., Filiaci, V. L., Mundt, A. J., Ridderstråle, K., Olopade, O. I., & Fleming, G. F. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.09.007 · Cited by 180
Khalifa, M. A., Mannel, R. S., Haraway, S. D., Walker, J., & Min, K.-W. (1994) · Gynecologic Oncology · doi:10.1006/gyno.1994.1092 · Cited by 162
Press, M. F., Sauter, G., Buyse, M. E., Fourmanoir, H., Quinaux, E., Tsao-Wei, D. D., EIERMANN, W., Robert, N. J., Pieńkowski, T., Crown, J. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6693 · Cited by 142
Santin, A. D., Bellone, S., Siegel, E. R., Palmieri, M., Thomas, M., Cannon, M. J., Kay, H., Roman, J. J., Burnett, A., & Pecorelli, S. L. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.10.605 · Cited by 141
Self-citationRevised FIGO Staging System for Endometrial Cancer
Lewin, S. N. (2011) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e3182185baa · Cited by 131
Villella, J., COHEN, S., Smith, D. H., Hibshoosh, H. H., & Hershman, D. L. (2006) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-00009577-200609000-00027 · Cited by 123
Uterine serous and grade 3 endometrioid carcinomas
Boruta, D. M., Gehrig, P. A., Groben, P. A., Bae-Jump, V. L., Boggess, J. F., Fowler, W. C., & Le, L. V. (2004) · Cancer · doi:10.1002/cncr.20645 · Cited by 122
Fader, A. N., Nagel, C. I., Axtell, A. E., Zanotti, K. M., Kelley, J. L., Moore, K. N., Secord, A. A., Walsh, C., Huh, W. K., Gehrig, P. A., et al. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.11.016 · Cited by 85
Self-citationEarly stage uterine serous carcinoma: Management updates and genomic advances
Fader, A. N., Santin, A. D., & Gehrig, P. A. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.01.004 · Cited by 52
Self-citation
Cited by
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
León-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., Leary, A., Nijman, H. W., Singh, N., Pollock, P. M., Bessette, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00549 · Cited by 855
Makker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
Lu, K. H., & Broaddus, R. R. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1514010 · Cited by 663
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Oaknin, A., Bosse, T. J., Creutzberg, C. L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M. R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.009 · Cited by 652
Metadata
- Authors
- Fader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O., Chambers, S. K., Secord, A. A., Havrilesky, L., O’Malley, D. M., Backes, F., Nevadunsky, N., Edraki, B., Pikaart, D., Lowery, W., ElSahwi, K. S., Celano, P., Bellone, S., Azodi, M., Litkouhi, B., Ratner, E., Silasi, D.-A., Schwartz, P. E., & Santin, A. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-07-10
- Volume
- 36
- Issue
- 20
- Pages
- 2044-2051
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2794839527
- Cited by
- 516
- References
- 22
- FWCI
- 43.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.